J M Aguado1, V J Anttila2, T Galperine3, S D Goldenberg4, S Gwynn5, D Jenkins6, T Norén7, N Petrosillo8, H Seifert9, A Stallmach10, T Warren5, C Wenisch11. 1. University Hospital 12 de Octubre, Madrid, Spain. 2. Helsinki University and Helsinki University Hospital, Finland. 3. Hôpital Claude Huriez, Lille, France. 4. Centre for Clinical Infection and Diagnostics Research, Guy's and St Thomas' NHS Foundation Trust, and King's College, London, UK. Electronic address: Simon.goldenberg@gstt.nhs.uk. 5. Triducive Ltd, St Albans, UK. 6. University Hospitals of Leicester NHS Trust, Leicester, UK. 7. Örebro University Hospital, Örebro, Sweden. 8. National Institute for Infectious Diseases, Rome, Italy. 9. Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany. 10. Department of Internal Medicine IV, Universitätsklinikum Jena, Germany. 11. Süd Kaiser Franz Josef Spital, Vienna, Austria.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is the leading cause of infectious nosocomial diarrhoea in Europe. Despite increased focus, its incidence and severity are increasing in many European countries. AIM: We developed a series of consensus statements to identify unmet clinical needs in the recognition and management of CDI. METHODS: A consortium of European experts prepared a series of 29 statements representing their collective views on the diagnosis and management of CDI in Europe. The statements were grouped into the following six broad themes: diagnosis; definitions of severity; treatment failure, recurrence and its consequences; infection prevention and control interventions; education and antimicrobial stewardship; and National CDI clinical guidance and policy. These statements were reviewed using questionnaires by 1047 clinicians involved in managing CDI, who indicated their level of agreement with each statement. FINDINGS: Levels of agreement exceeded the 66% threshold for consensus for 27 out of 29 statements (93.1%), indicating strong support. Variance between countries and specialties was analysed and showed strong alignment with the overall consensus scores. CONCLUSION: Based on the consensus scores of the respondent group, recommendations are suggested for the further development of CDI services in order to reduce transmission and recurrence and to ensure that appropriate diagnosis and treatment strategies are applied across all healthcare settings.
BACKGROUND:Clostridium difficileinfection (CDI) is the leading cause of infectious nosocomial diarrhoea in Europe. Despite increased focus, its incidence and severity are increasing in many European countries. AIM: We developed a series of consensus statements to identify unmet clinical needs in the recognition and management of CDI. METHODS: A consortium of European experts prepared a series of 29 statements representing their collective views on the diagnosis and management of CDI in Europe. The statements were grouped into the following six broad themes: diagnosis; definitions of severity; treatment failure, recurrence and its consequences; infection prevention and control interventions; education and antimicrobial stewardship; and National CDI clinical guidance and policy. These statements were reviewed using questionnaires by 1047 clinicians involved in managing CDI, who indicated their level of agreement with each statement. FINDINGS: Levels of agreement exceeded the 66% threshold for consensus for 27 out of 29 statements (93.1%), indicating strong support. Variance between countries and specialties was analysed and showed strong alignment with the overall consensus scores. CONCLUSION: Based on the consensus scores of the respondent group, recommendations are suggested for the further development of CDI services in order to reduce transmission and recurrence and to ensure that appropriate diagnosis and treatment strategies are applied across all healthcare settings.
Authors: Marcin Dembek; Abigail Kelly; Anna Barwinska-Sendra; Emma Tarrant; Will A Stanley; Daniela Vollmer; Jacob Biboy; Joe Gray; Waldemar Vollmer; Paula S Salgado Journal: Mol Microbiol Date: 2018-11 Impact factor: 3.501
Authors: Charmaine Normington; Ines B Moura; Jessica A Bryant; Duncan J Ewin; Emma V Clark; Morgan J Kettle; Hannah C Harris; William Spittal; Georgina Davis; Matthew R Henn; Christopher B Ford; Mark H Wilcox; Anthony M Buckley Journal: NPJ Biofilms Microbiomes Date: 2021-02-05 Impact factor: 7.290
Authors: S D Goldenberg; S Brown; L Edwards; D Gnanarajah; P Howard; D Jenkins; D Nayar; M Pasztor; S Oliver; T Planche; J A T Sandoe; P Wade; L Whitney Journal: Eur J Clin Microbiol Infect Dis Date: 2015-12-12 Impact factor: 3.267
Authors: Anthony M Buckley; Ines B Moura; James Altringham; Duncan Ewin; Emma Clark; Karen Bentley; Vikki Wilkinson; William Spittal; Georgina Davis; Mark H Wilcox Journal: J Antimicrob Chemother Date: 2021-12-24 Impact factor: 5.790